Amgen today announced the termination of its co-development and commercialisation agreement with AstraZeneca for brodalumab, an investigational IL-17 receptor inhibitor in development for patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis.
AstraZeneca meddelar i dag sina planer på att investera cirka 285 miljoner USD i en ny högteknologisk anläggning för tillverkning av biologiska läkemedel i Gärtuna utanför Södertälje. Den nya anläggningen kommer fokusera på fyllning och packning av proteinläkemedel. Det förväntas att den nya enheten kommer att producera läkemedel till kliniska prövningsprogram för AstraZeneca och Medimmune, koncer
AstraZeneca and MedImmune, the Company’s global biologics research and development arm, will demonstrate rapid progress with their combination-focused oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, 29 May-2 June 2015
AstraZeneca today announced that it has entered an agreement with Abbott, a global healthcare company, to develop companion diagnostic tests to identify patients with severe asthma who are most likely to benefit from the investigational biological therapy, tralokinumab.
AstraZeneca today announced a collaboration with the Montreal Heart Institute (MHI) in Quebec, Canada, to search the genomes of up to 80,000 patients for genes associated with cardiovascular diseases and diabetes, their complications and treatment outcomes.
Idag tilldelas Leg.läk. Professor Rolf Lewensohn, verksam vid Karolinska Institutet och Överläkare vid Onkologiska kliniken Karolinska Universitetssjukhuset i Stockholm, SLUSG-stipendiet 2015.
AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) and granted Priority Review for BRILINTA® (ticagrelor) tablets for patients with a history of heart attack. The sNDA is based on the results of the PEGASUS-TIMI 54 study, a large-scale outcomes trial in more than 21,000 patients that investigated ticagrelor tablets plu
Encouraging new data of relevance to Global public health crisis, presented at 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Det finansiella resultatet för kvartal 1 2015 ger stöd åt upprepad helårsprognos för 2015.
oTotala intäkter (definierat som produktförsäljning och intäkter från externa samarbeten1) ökade med 1% i fasta valutakurser 2 (CER) till 6 057 MUSD (Q1 2014: 6 460 MUSD)
oVinst per aktie för kärnverksamheten (Core EPS) minskade med 3% till1,08 USD i takt med att vi fortsätter att investera i att uppn
AstraZeneca and MedImmune, the Company’s global biologics research and development arm, today announced that they have entered into an exclusive collaboration agreement with Celgene Corporation, a global leader in haematological cancers, for the development and commercialisation of MEDI4736
AstraZeneca and MedImmune, the Company’s global biologics research and development arm, today announced that they have entered into a collaboration to accelerate and broaden the development of Innate Pharma SA’s proprietary anti-NKG2A antibody
Idag tilldelas Berglind Libungans, verksam vid enheten för kardiologi, Sahlgrenska Universitetssjukhuset i Göteborg ett forskningsstipendium på 120 000 kr.
AstraZeneca and Bina Technologies, Inc., a member of the Roche Group, today announced that they have entered into an agreement for AstraZeneca to become the first member to join the Bina Alliance Programme
Uppdaterade data som presenterades vid European Lung Cancer Conference 2015 visar en fördröjning av tumörprogression på över ett år
AstraZeneca today announced that the US Food and Drug Administration has granted Orphan Drug Designation for the MEK inhibitor selumetinib, for the treatment of uveal melanoma.
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a collaboration to conduct clinical trials in immuno-oncology with Immunocore Limited, a privately-held UK-based biotechnology company.
AstraZeneca meddelar i dag att den amerikanska läkemedelsmyndigheten (Food and Drug Administration, FDA) har beviljat särläkemedelsstatus åt den monoklonala anti-CTLA-4-antikroppen tremelimumab för behandling av malignt mesoteliom.
AstraZeneca today announced that the US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 13to 1(1 abstained; 15 total votes) that the results of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with
•More than 60 scientific abstracts to be featured at the meeting, highlighting the breadth and depth of AstraZeneca’s oncology pipeline and ability to test a range of small molecule and biologic combinations.
Nu finns AstraZenecas läkemedel Moventig® (naloxegol) tillgängligt i Sverige, som första land i Europa. Läkemedlet är avsett för att behandla förstoppning orsakad av smärtlindrande läkemedel innehållande opioider hos vuxna patienter som upplevt otillräcklig effekt av laxermedel